Home › Activist investors › Tang Capital
Other large holder. Positions and campaigns from Tang Capital’s SEC filings. Updated November 20, 2026.
Active campaign Public letter or presentation filed · Jun 30, 2026
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. | 13.63%7,285,085 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 14, 2026 | Nov 14, 2025 | Increased Nov 16, 2026 | ▲ 5.69 pts | Increased | 13F: none stated |
| Boundless Bio, Inc. | 12.49%2,840,635 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 5, 2026 | Aug 14, 2026 | Increased Nov 16, 2026 | ▲ 1.23 pts | Increased | 13F: none stated |
| Fulcrum Therapeutics, Inc. | 9.28%7,080,945 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 23, 2026 | Aug 14, 2026 | Increased Nov 16, 2026 | ▲ 0.73 pts | Increased | 13F: none stated |
| Nano Dimension Ltd. | 7.9%16,715,812 shares | Schedule 13D/A, filed Jul 27, 2026 | Jun 30, 2026 | Increased Jul 27, 2026 | ▲ 1.10 pts | Active campaign | Seeks changes or engagement |
| Immunocore Holdings Plc | 5.58%2,884,149 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 | May 16, 2022 | Increased Nov 16, 2026 | ▲ 0.44 pts | Increased | 13F: none stated |
| AnaptysBio, Inc. | 4.93%1,474,262 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 16, 2026 | Feb 14, 2020 | Increased Nov 16, 2026 | ▲ 0.36 pts | Increased | 13F: none stated |
| Heron Therapeutics, Inc. | 4.73%8,971,427 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 5, 2026 | May 15, 2014 | Increased Nov 16, 2026 | ▲ 1.43 pts | Increased | 13F: none stated |
| Tarsus Pharmaceuticals, Inc. | 3.89%1,917,666 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 | May 16, 2022 | Increased Nov 16, 2026 | ▲ 0.32 pts | Increased | 13F: none stated |
| Compass Pathways PLC | 3.67%5,200,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 28, 2026 | Feb 14, 2025 | Increased Nov 16, 2026 | ▲ 0.06 pts | Increased | 13F: none stated |
| Ardelyx, Inc. | 3.60%9,047,134 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Celcuity Inc. | 2.98%1,464,594 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 | Nov 14, 2025 | Increased Nov 16, 2026 | ▲ 0.29 pts | Increased | 13F: none stated |
| Aurinia Pharmaceuticals Inc. | 10.0%13,044,106 shares | Schedule 13D/A, filed Jun 4, 2026 | Sep 12, 2024 | Increased Jun 4, 2026 | ▲ 0.80 pts | — | Investment purposes |
| Compass Therapeutics, Inc. | 9.99%17,990,782 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 28, 2026 | Nov 14, 2024 | — | 0.00 pts | — | 13F: none stated |
| Pliant Therapeutics, Inc. | 9.6%5,859,044 shares | Schedule 13D, filed Mar 10, 2025 | Mar 10, 2025 | — | — | — | Seeks changes or engagement |
| Galapagos NV | 7.5%4,910,525 shares | Schedule 13D, filed Feb 14, 2025 | Feb 14, 2025 | — | — | — | Investment purposes |
| Nuvectis Pharma, Inc. | 5.95%1,577,968 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 1, 2026 | Aug 14, 2026 | — | ▲ 0.11 pts | — | 13F: none stated |
| Journey Medical Corporation | 5.90%1,610,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Nov 14, 2023 | — | 0.00 pts | — | 13F: none stated |
| Crescent Biopharma, Inc. | 3.12%1,160,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 27, 2026 | Aug 14, 2025 | — | 0.00 pts | — | 13F: none stated |
| Spyre Therapeutics, Inc. | 1.99%1,892,200 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 | May 15, 2025 | — | ▼ 0.15 pts | — | 13F: none stated |
| Mirum Pharmaceuticals, Inc. | 1.89%1,236,027 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Aug 15, 2022 | — | ▼ 0.01 pts | — | 13F: none stated |
| PTC Therapeutics, Inc. | 1.80%1,500,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 | Feb 14, 2024 | — | 0.00 pts | — | 13F: none stated |
| Precigen, Inc. | 1.79%6,417,500 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Nov 14, 2024 | — | 0.00 pts | — | 13F: none stated |
| Viridian Therapeutics, Inc. | 1.58%1,792,626 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Aug 15, 2022 | — | 0.00 pts | — | 13F: none stated |
| LENZ Therapeutics, Inc. | 1.44%451,114 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 28, 2026 | May 15, 2024 | — | 0.00 pts | — | 13F: none stated |
| Corcept Therapeutics Inc. | 1.37%1,500,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 22, 2026 | Feb 17, 2026 | — | ▼ 0.02 pts | — | 13F: none stated |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“…the Issuer, including, but not limited to, its businesses, operations and prospects. In light of that ongoing evaluation, on June 30, 2026, TCM sent a merger proposal to the Issuer outlining the principal terms on which it would effect a merger between the Issuer and an affiliate of the Reporting Persons (see Exhibit 2). The merger proposal provides that it is subject to limited confirmatory diligence, as well as the execution of a definitive merger…”
Item 4 in the Schedule 13D/A filed Jul 27, 2026; this amendment did not restate Item 4, so the text is from the filing of Jun 30, 2026.
“Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and…”
“…its representatives and/or other stockholders, seek to enter into a confidentiality agreement with the Issuer and/or discuss with the Issuer different strategic alternatives or changes to the Issuer's operations. There can be no certainty as to whether discussions with the Issuer will occur, the outcome of any such discussions or whether the Reporting Persons will take any actions relating to the Issuer. Subject to applicable law and regulation, the…”
“The Reporting Persons purchased the Shares and options reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including, but not limited to, its businesses, operations and prospects. The Reporting Persons may engage…”
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Jounce Therapeutics, Inc. | Settled (agreement with the company) | Mar 27, 2023 | Mar 27, 2023 | — | latest (1) | — |
| Aptevo Therapeutics Inc. | No campaign filings in the last 12 months | Feb 9, 2021 | Feb 9, 2021 | Soliciting material filed | latest (1) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Capricor Therapeutics, Inc. | 7.05% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Aug 13, 2026 | Not in the latest 13F | Nov 16, 2026 |
| Kezar Life Sciences, Inc. | 0.0% | Schedule 13D/A, filed May 13, 2026 | Exited | May 13, 2026 |
| ESSA Pharma Inc. | 9.7% | Schedule 13D, filed Nov 8, 2024 | Not in the 13F for the quarter ended Sep 30, 2025 | Nov 14, 2025 |
| Cargo Therapeutics, Inc. | 100.0% | Schedule 13D/A, filed Aug 21, 2025 | Not in the 13F for the quarter ended Sep 30, 2025 | Nov 14, 2025 |
| ITeos Therapeutics, Inc. | 100.0% | Schedule 13D/A, filed Sep 3, 2025 | Not in the 13F for the quarter ended Sep 30, 2025 | Nov 14, 2025 |
| HilleVax, Inc. | 0.0% | Schedule 13D/A, filed Sep 19, 2025 | Exited | Sep 19, 2025 |
| Allakos Inc. | 100.0% | Schedule 13D/A, filed May 19, 2025 | Not in the 13F for the quarter ended Jun 30, 2025 | Aug 14, 2025 |
| Acelyrin, Inc. | 0.0% | Schedule 13D/A, filed May 23, 2025 | Exited | May 23, 2025 |
| Singular Genomics Systems, Inc. | 14.9% | Schedule 13D, filed Sep 18, 2024 | Not in the 13F for the quarter ended Mar 31, 2025 | May 15, 2025 |
| Reneo Pharmaceuticals, Inc. | 10.0% | Schedule 13D, filed Dec 26, 2023 | Not in the 13F for the quarter ended Dec 31, 2024 | Feb 14, 2025 |
| Theseus Pharmaceuticals, Inc. | 100.0% | Schedule 13D/A, filed Feb 16, 2024 | Not in the 13F for the quarter ended Mar 31, 2024 | May 15, 2024 |
| LianBio | 8.6% | Schedule 13D, filed Nov 30, 2023 | Not in the 13F for the quarter ended Mar 31, 2024 | May 15, 2024 |
| Rain Oncology Inc. | 0.0% | Schedule 13D/A, filed Feb 2, 2024 | Exited | Feb 2, 2024 |
| Atea Pharmaceuticals, Inc. | 4.8% | Schedule 13D/A, filed Nov 28, 2023 | Reported below 5% in a 13D/A | Nov 28, 2023 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Nano Dimension Ltd. | Ongoing | Public letter or presentation filed | Jun 30, 2026 | Jun 30, 2026 |
| Jounce Therapeutics, Inc. | Settlement | agreement with the company | Mar 27, 2023 | Mar 27, 2023 |
| Aptevo Therapeutics Inc. | No outcome in the filings read | — | Feb 9, 2021 | Feb 9, 2021 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 1 of 17 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
| Company | First 13D | To latest close | SPY same dates | 6 months after | 12 months after |
|---|---|---|---|---|---|
| Nano Dimension Ltd. NNDM | Jun 30, 2026 | -20.7%Jun 30, 2026 – Nov 18, 2026 | -2.2% | not yet / no price | not yet / no price |
Prices: daily closes (Nasdaq), as stored by the site.
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Tang Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| Millennium Management LLC | Schedule 13G | Aug 11, 2026 | 5.7% |
| Rubric Capital Management LP | Schedule 13G | Aug 14, 2026 | 6.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| RA Capital Management, L.P. | Schedule 13G | Feb 17, 2026 | 9.9% |
| Nantahala Capital Management, LLC | Schedule 13G | May 15, 2026 | 4.6% |
| TCG Crossover GP II, LLC | Schedule 13G | May 15, 2026 | 7.9% |
| EcoR1 Capital, LLC | Schedule 13G | Jun 25, 2026 | 9.0% |
| BlackRock Portfolio Management LLC | Schedule 13G | Jul 17, 2026 | 6.0% |
| BlackRock, Inc. | Schedule 13G | Jul 28, 2026 | 7.2% |
| Bank of America Corp /De/ | Schedule 13G | Aug 3, 2026 | 6.7% |
| Montanova Capital, LLC | Schedule 13G | Aug 14, 2026 | 5.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Oramed Pharmaceuticals Inc. | Schedule 13D | Jan 29, 2026 | 5.0% |
| Steel Partners | 13F | Aug 7, 2026 | 2.8% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Renaissance Technologies LLC | Schedule 13G | Feb 12, 2026 | 5.5% |
| Ingalls & Snyder LLC | Schedule 13G | Apr 21, 2026 | 6.8% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Baker Bros. Advisors LP | Schedule 13D | Aug 1, 2025 | 18.9% |
| Perceptive Advisors LLC | Schedule 13G | Aug 4, 2025 | 6.5% |
| Lance G. Laing | Schedule 13G | Nov 13, 2025 | 3.6% |
| Brian F. Sullivan | Schedule 13G | Nov 13, 2025 | 9.1% |
| BVF Partners L P/Il | Schedule 13G | Nov 14, 2025 | 1.6% |
| Soleus Capital Management, L.P. | Schedule 13G | Feb 12, 2026 | 3.9% |
| Avoro Capital Advisors LLC | Schedule 13G | Feb 17, 2026 | 6.7% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Fairmount Funds Management LLC | Schedule 13D | Jun 23, 2025 | 20.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| EcoR1 Capital, LLC | Schedule 13D | May 16, 2025 | 27.9% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| The Vanguard Group | Schedule 13G | Jan 30, 2025 | 5.0% |
| BlackRock, Inc. | Schedule 13G | Feb 5, 2025 | 6.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| RTW Investments, LP | Schedule 13G | Feb 14, 2025 | 6.2% |
| Perceptive Advisors LLC | Schedule 13G | Feb 14, 2025 | 4.4% |
| Venrock Healthcare Capital Partners III, L.P. | Schedule 13G | Feb 14, 2025 | 4.6% |
| BlackRock, Inc. | Schedule 13G | Jul 16, 2025 | 6.6% |
| The Vanguard Group | Schedule 13G | Jul 29, 2025 | 5.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Redmile Group, LLC | Schedule 13G | Feb 14, 2025 | 4.8% |
| FMR LLC | Schedule 13G | Mar 7, 2025 | 0.2% |
| T. Rowe Price Associates, Inc. | Schedule 13G | May 14, 2025 | 0.1% |
| BlackRock, Inc. | Schedule 13G | Jul 17, 2025 | 3.4% |
| The Vanguard Group | Schedule 13G | Jul 29, 2025 | 4.9% |
| Morgan Stanley | Schedule 13G | Aug 6, 2025 | 6.1% |
| Deep Track Capital, LP | Schedule 13G | Aug 14, 2025 | 6.4% |
| Point72 Asset Management, L.P. | Schedule 13G | Sep 4, 2025 | 6.7% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Trium Capital LLP | Schedule 13D | Mar 6, 2025 | 5.4% |
| Madison Avenue International LP | Schedule 13D | Apr 30, 2025 | 5.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| EcoR1 Capital, LLC | Schedule 13D | Aug 23, 2024 | 9.9% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Deep Track Capital, LP | Schedule 13G | Jan 17, 2025 | 10.0% |
| Millennium Management LLC | Schedule 13G | Feb 6, 2025 | 3.7% |
| George Jay Goldsmith | Schedule 13G | Feb 13, 2025 | 2.6% |
| Kenneth Griffin | Schedule 13G | Feb 14, 2025 | 1.7% |
| RTW Investments, LP | Schedule 13G | May 15, 2025 | 8.3% |
| Vivo Opportunity Fund Holdings, L.P. | Schedule 13G | May 15, 2025 | 6.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Patient Capital Management, LLC | Schedule 13G | Feb 12, 2025 | 6.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Biotechnology Value Fund LP | Schedule 13D | Apr 9, 2025 | 19.7% |
| Soleus Capital Master Fund, L.P. | Schedule 13D | Apr 15, 2025 | 5.1% |
| BML Investment Partners, L.P. | Schedule 13D | Apr 24, 2025 | 9.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Flynn James E | Schedule 13D | Sep 12, 2024 | 6.7% |
| CRCM LP | Schedule 13D | Nov 5, 2024 | 5.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Armistice Capital, LLC | Schedule 13G | Feb 14, 2025 | 4.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Ra Capital Management, L.P. | Schedule 13D | Mar 28, 2024 | 0.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| BML Capital | 13F | Jul 24, 2023 | 8.4% |